Quadrupling after an experimental drug blocks the return of Breast Cancer in women. Blue chip records, the s p 500 fyl out a small gai 300 , thats quadruple. Another big gainer saw shares climb 11 on surging sales of its ms treatment. Meg terrell has more on this big day in biotech, what is behind the numbers at puma and bio again and what investors can look forward to. Reporter stocks are known for versatility, big risk, big reward. Puma soared on the drug for Breast Cancer. In a trial of more than 2,000 patients the medicine helps people live for 33 longer without disease professing. The drug was tested for a specific genetic mutation. It will apply for approval in the first half of next year. It would bring in 4 billion according to estimates. The results may also make puma a likely acquisition target analysts said. The ceo is known for deal making. He sold the last company, couger biotech to Johnson Johnson for a billion dollars in 2009 and a blowout day for the company that topped
Experimental drug blocks the return of Breast Cancer in women. Blue chip records, the s p 500 fyl out a small gai 300 , thats quadruple. Another big gainer saw shares climb 11 on surging sales of its ms treatment. Meg terrell has more on this big day in biotech, what is behind the numbers at puma and bio again and what investors can look forward to. Reporter stocks are known for versatility, big risk, big reward. Puma soared on the drug for Breast Cancer. In a trial of more than 2,000 patients the medicine helps people live for 33 longer without disease professing. The drug was tested for a specific genetic mutation. It will apply for approval in the first half of next year. It would bring in 4 billion according to estimates. The results may also make puma a likely acquisition target analysts said. The ceo is known for deal making. He sold the last company, couger biotech to Johnson Johnson for a billion dollars in 2009 and a blowout day for the company that topped estimates for Second
Experimental drug blocks the return of Breast Cancer in women. Blue chip records, the s p 500 fyl out a small gai 300 , thats quadruple. Another big gainer saw shares climb 11 on surging sales of its ms treatment. Meg terrell has more on this big day in biotech, what is behind the numbers at puma and bio again and what investors can look forward to. Reporter stocks are known for versatility, big risk, big reward. Puma soared on the drug for Breast Cancer. In a trial of more than 2,000 patients the medicine helps people live for 33 longer without disease professing. The drug was tested for a specific genetic mutation. It will apply for approval in the first half of next year. It would bring in 4 billion according to estimates. The results may also make puma a likely acquisition target analysts said. The ceo is known for deal making. He sold the last company, couger biotech to Johnson Johnson for a billion dollars in 2009 and a blowout day for the company that topped estimates for Second
Experimental drug blocks the return of Breast Cancer in women. Blue chip records, the s p 500 fyl out a small gai 300 , thats quadruple. Another big gainer saw shares climb 11 on surging sales of its ms treatment. Meg terrell has more on this big day in biotech, what is behind the numbers at puma and bio again and what investors can look forward to. Reporter stocks are known for versatility, big risk, big reward. Puma soared on the drug for Breast Cancer. In a trial of more than 2,000 patients the medicine helps people live for 33 longer without disease professing. The drug was tested for a specific genetic mutation. It will apply for approval in the first half of next year. It would bring in 4 billion according to estimates. The results may also make puma a likely acquisition target analysts said. The ceo is known for deal making. He sold the last company, couger biotech to Johnson Johnson for a billion dollars in 2009 and a blowout day for the company that topped estimates for Second